Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy


      We sought to evaluate the safety and efficacy of TG4001 in patients with human papillomavirus (HPV) 16–related cervical intraepithelial neoplasia (CIN) 2/3 at 6 and 12 months.

      Study Design

      In all, 21 patients with HPV 16–related CIN 2/3 received 3 weekly subcutaneous injections of TG4001. Regression of the CIN 2/3 lesion and the clearance of HPV 16 infection were monitored by cytology, colposcopy, and HPV DNA/messenger RNA (mRNA) detection. A clinical response was defined by no CIN 2/3 found on conization, or no conization performed because not suspected at cytology or colposcopy.


      Ten patients (48%) were evaluated as clinical responders at month 6. Nine patients experienced an improvement of their HPV 16 infection, by mRNA ± DNA eradication. HPV 16 mRNA clearance was associated with CIN 2/3 cytologic and colposcopic regression in 7 of 10 patients. At month 12, 7 of 8 patients without conization reported neither suspicion of CIN 2/3 relapse nor HPV 16 infection. The remaining patient was lost to follow-up.


      These promising data warrant further development of TG4001 in CIN 2/3 treatment.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Prétet J.L.
        • Jacquard A.C.
        • Carcopino X.
        • et al.
        Human papillomavirus (HPV) genotype distribution in invasive cervical cancers in France: EDITH study.
        Int J Cancer. 2008; 122: 428-432
        • Bergeron C.
        • Breugelmans J.G.
        • Bouée S.
        • Lorans C.
        • Bénard S.
        • Rémy V.
        Cervical cancer screening and associated treatment costs in France.
        Gynecol Obstet Fertil. 2006; 34: 1036-1042
        • Martin-Hirsch P.L.
        • Paraskevaidis E.
        • Kitchener H.
        Surgery for cervical intraepithelial neoplasia.
        Cochrane Database Syst Rev. 2000; 2 (CD001318)
        • Arbyn M.
        • Kyrgiou M.
        • Simoens C.
        • et al.
        Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis.
        BMJ. 2008; 337: a1284
        • Kreimer A.R.
        • Guido R.S.
        • Solomon D.
        • et al.
        Human papillomavirus testing following loop electrosurgical excision procedure identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or 3 disease.
        Cancer Epidemiol Biomarkers Prev. 2006; 15: 908-914
        • Paavonen J.
        • Naud P.
        • Salmerón J.
        • et al.
        Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomized study in young women.
        Lancet. 2009; 374: 301-314
        • Kjaer S.K.
        • Sigurdsson K.
        • Iversen O.E.
        • et al.
        A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions.
        Cancer Prev Res (Phila). 2009; 2: 868-878
        • Hildesheim A.
        • Herrero R.
        • Wacholder S.
        • et al.
        Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial.
        JAMA. 2007; 298: 743-753
        • O'Shaughnessy J.A.
        • Kelloff G.J.
        • Gordon G.B.
        • et al.
        Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development.
        Clin Cancer Res. 2002; 8: 314-346
        • Walker P.
        • Dexeus S.
        • De Palo G.
        • et al.
        • Nomenclature Committee of the International Federation for Cervical Pathology and Colposcopy
        International terminology of colposcopy: an updated report from the International Federation for Cervical Pathology and Colposcopy.
        Obstet Gynecol. 2003; 101: 175-177
        • Solomon D.
        • Davey D.
        • Kurman R.
        • et al.
        The 2001 Bethesda system: terminology for reporting results of cervical cytology.
        JAMA. 2002; 287: 2114-2119
        • Richart R.M.
        Cervical intraepithelial neoplasia.
        Pathol Annu. 1973; 8: 301-328
        • Rouzier R.
        Management of CIN1.
        J Gynecol Obstet Biol Reprod. 2008; 37: S114-S120
        • Bousquet C.
        • Lagier G.
        • Lillo-Le Louët A.
        • Le Beller C.
        • Venot A.
        • Jaulent M.C.
        Appraisal of the MedDRA conceptual structure for describing and grouping adverse drug reactions.
        Drug Saf. 2005; 28: 19-34
        • Garcia F.
        • Petry K.U.
        • Muderspach L.
        • et al.
        ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial.
        Obstet Gynecol. 2004; 103: 317-326
        • Trimble C.L.
        • Piantadosi S.
        • Gravitt P.
        • et al.
        Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype.
        Clin Cancer Res. 2005; 11: 4717-4723
        • Muderspach L.
        • Wilczynski S.
        • Roman L.
        • et al.
        A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive.
        Clin Cancer Res. 2000; 6: 3406-3416
        • Einstein M.H.
        • Kadish A.S.
        • Burk R.D.
        • et al.
        Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III.
        Gynecol Oncol. 2007; 106: 453-460
        • Roman L.D.
        • Wilczynski S.
        • Muderspach L.I.
        • et al.
        A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia.
        Gynecol Oncol. 2007; 106: 558-566
        • Frazer I.H.
        • Quinn M.
        • Nicklin J.L.
        • et al.
        Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia.
        Vaccine. 2004; 23: 172-181
        • Trimble C.L.
        • Peng S.
        • Kos F.
        • et al.
        A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3.
        Clin Cancer Res. 2009; 15: 361-367
        • Kaufmann A.M.
        • Nieland J.D.
        • Jochmus I.
        • et al.
        Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3).
        Int J Cancer. 2007; 121: 2794-2800
        • Garcia-Hernandez E.
        • Gonzalez-Sanchez J.L.
        • Andrade-Manzano A.
        • et al.
        Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine.
        Cancer Gene Ther. 2006; 13: 592-597
        • Castle P.E.
        • Dockter J.
        • Giachetti C.
        • et al.
        A cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical precancer and cancer.
        Clin Cancer Res. 2007; 13: 2599-2605
        • Cattani P.
        • Zannoni G.F.
        • Ricci C.
        • et al.
        Clinical performance of human papillomavirus E6 and E7 mRNA testing for high-grade lesions of the cervix.
        J Clin Microbiol. 2009; 47: 3895-3901
        • Keegan H.
        • McInerney J.
        • Pilkington L.
        • et al.
        Comparison of HPV detection technologies: hybrid capture 2, PreTect HPV-Proofer and analysis of HPV DNA viral load in HPV16, HPV18 and HPV33 E6/E7 mRNA positive specimens.
        J Virol Methods. 2009; 155: 61-66
        • Bulkmans N.W.
        • Berkhof J.
        • Bulk S.
        • et al.
        High-risk HPV type-specific clearance rates in cervical screening.
        Br J Cancer. 2007; 96: 1419-1424
        • Moscicki A.B.
        • Schiffman M.
        • Kjaer S.
        • Villa L.L.
        Updating the natural history of HPV and anogenital cancer.
        Vaccine. 2006; 24: S42-S51